[{"id":"d089607a-1031-4001-af05-f61c61e55845","acronym":"","url":"https://clinicaltrials.gov/study/NCT02013648","created_at":"2021-01-18T09:12:24.696Z","updated_at":"2024-07-02T16:35:17.930Z","phase":"Phase 3","brief_title":"Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)","source_id_and_acronym":"NCT02013648","lead_sponsor":"University of Ulm","biomarkers":" RUNX1 • RUNX1T1","pipe":" | ","alterations":" RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion","tags":["RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • daunorubicin • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 204","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2024-02-23"},{"id":"9a349e3d-c04d-4a0c-8ba8-e2c65537d627","acronym":"RETRO-CBF","url":"https://clinicaltrials.gov/study/NCT05070208","created_at":"2021-10-07T12:53:00.876Z","updated_at":"2024-07-02T16:35:21.574Z","phase":"","brief_title":"Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor","source_id_and_acronym":"NCT05070208 - RETRO-CBF","lead_sponsor":"Acute Leukemia French Association","biomarkers":" RUNX1 • RUNX1T1","pipe":" | ","alterations":" RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion","tags":["RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion"],"overall_status":"Completed","enrollment":" Enrollment 400","initiation":"Initiation: 09/22/2021","start_date":" 09/22/2021","primary_txt":" Primary completion: 01/25/2024","primary_completion_date":" 01/25/2024","study_txt":" Completion: 01/25/2024","study_completion_date":" 01/25/2024","last_update_posted":"2024-01-31"},{"id":"344dd84f-cbb2-4195-9057-7e6bb67aba39","acronym":"","url":"https://clinicaltrials.gov/study/NCT01238211","created_at":"2021-01-18T04:59:02.957Z","updated_at":"2024-07-02T16:35:54.402Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT01238211","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RUNX1 • RUNX1T1","pipe":" | ","alterations":" RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion","tags":["RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 12/14/2010","start_date":" 12/14/2010","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 03/15/2021","study_completion_date":" 03/15/2021","last_update_posted":"2023-03-01"}]